RedHill Biopharma (RDHL) Investor Presentation - Slideshow

Company Overview - RedHill Biopharma is an emerging U S specialty biopharmaceutical company focused on commercialization and development of drugs for gastrointestinal and infectious diseases[8] - The company has a strong U S commercial footprint with a sales force of approximately 100 representatives and 30 field support professionals promoting 3 FDA-approved drugs[14,35] - As of March 31, 2021, RedHill Biopharma had a cash balance of approximately $92 million[17] - The company's market capitalization is approximately $333 million[17] Commercial Products - Movantik is FDA-approved for opioid-induced constipation (OIC) in adults with chronic non-cancer pain and has patent protection extending until at least 2028[11,43] - Talicia is FDA-approved for the treatment of Helicobacter pylori infection in adults and is eligible for extended market exclusivity for a total of 8 years under QIDP designation, with patent protection extending until at least 2034[11,68] - Aemcolo is FDA-approved for the treatment of travelers' diarrhea caused by noninvasive strains of E coli in adults and has U S marketing exclusivity through 2028[11,114] Pipeline Products - RHB-204 is targeting pulmonary nontuberculous Mycobacteria (NTM) disease, with a U S Phase 3 study ongoing and a U S market potential estimated at approximately $530 million in 2021[13,147] - RHB-104 for Crohn's disease met its primary endpoint in a Phase 3 study, with the worldwide market estimated to exceed $12 8 billion in 2022[13,162] - Opaganib is a first-in-class SK2 inhibitor with ongoing Phase 2/3 COVID-19 & Phase 2 oncology program[13]